Resources
84 Results (showing 31 - 40)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/20/2022 (updated 3/27/2024)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 3/22/2022 (updated 3/27/2024)
Yesterday, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), is announcing two grant programs totaling $25.6 million that will expand access to medication-assisted treatment for opioid use disorder and prevent the misuse of prescription drugs. By reducing barriers to accessing the most effective, evidenced-based treatments, this funding reflects the priorities of HHS' Overdose Prevention Strategy, as well as its new initiative to strengthen the nation's mental health and crisis care systems.
Posted 3/9/2022 (updated 3/27/2024)
A disproportionate number of people in jails have substance use disorders (SUDs).1 Incarceration provides a valuable opportunity for identifying SUD and addressing withdrawal.* Within the first few hours and days of detainment, individuals who have suddenly stopped using alcohol, opioids, or other drugs may experience withdrawal symptoms, particularly when they have used the substances heavily or long-term. Without its identification and timely subsequent medical attention, withdrawal can lead to serious injury or death. Deaths from withdrawal are preventable, and jail administrators have a pressing responsibility to establish and implement withdrawal policy and protocols that will save lives and ensure legal compliance. This brief describes the scope of the challenge, provides an overview of constitutional rights and key legislation related to substance use withdrawal, and outlines steps for creating a comprehensive response to SUD.
Posted 11/11/2021 (updated 4/3/2024)
JBS’s Robert Childs discussed the key concepts of harm reduction and evidence-based harm reduction interventions that grantees can implement to reduce overdose in their rural communities. Staff from Arkansas Behavioral Health Integration Network shared lessons learned from their RCORP-Planning grant in gaining buy-in for harm reduction concepts and planning for harm reduction services in rural Arkansas.
Posted 10/26/2021 (updated 4/3/2024)
Posted 10/18/2021 (updated 4/3/2024)
The MOUD Best Practices Webinar series takes a person-centered, outcomes-focused approach to presenting and discussing best practices in the use of medication for opioid use disorder (MOUD), starting with client engagement and initiation of MOUD, patient stabilization and retention in MOUD, and supporting recovery during MOUD. The focus of each presentation in the series will be on the application of best practices to meet your community’s goals for each of the three topic areas, including adapting them to your local resources while maintaining fidelity to their evidence base.
At the conclusion of Session 2 participants will be able to: describe specific best practices related to stabilization and retention in MOUD, connect best practices to the community’s outcomes and goals and adapt best practices to local needs and resources while maintaining fidelity to the evidence base
Presenter: Melinda Campopiano, MD (mcampopiano@jbsinternational.com)
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 8/4/2021 (updated 4/2/2024)